The text provides comprehensive financial information about Thermo Fisher Scientific Inc., detailing their condensed consolidated balance sheet, statement of income, statement of comprehensive income, cash flows, and statement of redeemable noncontrolling interest and equity for specified periods. It covers a range of topics such as costs, revenues by country, income taxes, debt, financing arrangements, income tax calculations, unrecognized tax benefits, earnings per share, debt obligations, commercial paper programs, credit facilities, senior notes, effective interest rates, settlement of an IRS audit, provision for income taxes, income tax credits, tax return reassessments and settlements, and valuation allowances. Additionally, it discusses the company's unrecognized tax benefits and the reconciliation of these benefits over a specific period.
The text provided discusses "Management's Discussion and Analysis of Financial Condition and Results of Operations" for Thermo Fisher Scientific Inc. The company's performance data for the three and nine months ended in October 2022 is outlined, including segments like Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. It mentions acquisitions made by the company in 2021, such as acquiring PPD, Inc., Mesa Biotech, Inc., and PeproTech, Inc. The text also covers non-operating items like interest expense, other income/expense, and tax rates. Additionally, it discusses liquidity, capital resources, free cash flow, non-GAAP measures used by the company, and mentions critical accounting policies and recent accounting pronouncements. The company's financial health, strategic growth investments, and outlook for the future are detailed in the document.
The company's exposure to market risk from changes in interest rates and currency exchange rates has not significantly changed from what was previously discussed in the Annual Report on Form 10-K for the year ended December 31, 2021.
Management at Thermo Fisher Scientific evaluated the effectiveness of the company's disclosure controls and procedures, with the CEO and CFO participating. They concluded that as of the specified period, the disclosure controls and procedures were effective at a reasonable assurance level. Additionally, there were no significant changes in the company's internal control over financial reporting in the fiscal quarter mentioned, which could materially affect its financial reporting.
The text discusses the presence of legal proceedings involving different aspects like product liability, intellectual property, employment, and commercial issues against the company. It directs to refer to Note 8 of the company's Condensed Consolidated Financial Statements under the section "Commitments and Contingencies" for further details.
The text refers to the disclosure of material risks to investors in the company's Annual Report on Form 10-K for the year ended December 31, 2021, found under the section titled "Risk Factors" and filed with the SEC.
In the mentioned text, it is stated that there was no share repurchase activity for the company in the third quarter of 2022. However, on September 23, 2021, the company's Board of Directors authorized the repurchase of up to $3.00 billion of the company's common stock. In the fourth quarter of 2022, the company repurchased $1.00 billion of the company's common stock, amounting to 2.0 million shares, which depleted the 2021 authorization.
I am here to assist you with summarizing the text you provided. Please go ahead and share the text so that I can summarize it for you.
I'm ready to receive the text parts for summarization. Please go ahead and provide them.
I’m sorry, but I cannot provide summaries based on incomplete information. Please provide all the text you would like me to summarize at once.
The text provides a list of exhibits related to certifications of the Chief Executive Officer and Chief Financial Officer required by Exchange Act Rules as adopted pursuant to the Sarbanes-Oxley Act of 2002, along with various XBRL documents. The certifications are noted not to be deemed "filed" for certain purposes. The document is signed by Stephen Williamson (Senior Vice President and Chief Financial Officer) and Joseph R. Holmes (Vice President and Chief Accounting Officer) on behalf of Thermo Fisher Scientific Inc. as of November 4, 2022.
